Table 3.
Relative frequency of clinical features, hormone receptor–positive, HER2-negative cases, Carolina Breast Cancer Study 3 (2008–2013)
| Clinical feature | Race and age, y |
P* | ||||
|---|---|---|---|---|---|---|
| All cases | Black |
White |
||||
| <50 | ≥50 | <50 | ≥50 | |||
| No. (%) | No. (%) | No. (%) | No. (%) | |||
| Tumor size, cm | ||||||
| ≤2 | 265 (55.1) | 36 (40.9) | 63 (54.3) | 69 (54.8) | 97 (64.2) | .006 |
| >2 | 216 (44.9) | 52 (59.1) | 53 (45.7) | 57 (45.2) | 54 (35.8) | |
| Missing | 11 | 1 | 3 | 1 | 6 | |
| >2 vs ≤ 2, OR (95% CI) | – | 2.60 (1.51 to 4.45) | 1.51 (0.92 to 2.48) | 1.48 (0.92 to 2.41) | 1.00 (reference) | |
| Nodal status | ||||||
| Negative | 277 (57.5) | 41 (46.6) | 70 (60.3) | 72 (56.7) | 94 (62.3) | .11 |
| Positive | 205 (42.5) | 47 (53.4) | 46 (39.7) | 55 (43.3) | 57 (37.8) | |
| Missing | 10 | 1 | 3 | 0 | 6 | |
| Positive vs negative, OR (95% CI) | – | 1.89 (1.11 to 3.22) | 1.08 (0.66 to 1.78) | 1.26 (0.78 to 2.04) | 1.00 (reference) | |
| Stage | ||||||
| I and II | 403 (83.6) | 71 (80.7) | 101 (87.1) | 104 (81.9) | 127 (84.1) | .60 |
| III and IV | 79 (16.4) | 17 (19.3) | 15 (12.9) | 23 (18.1) | 24 (15.9) | |
| Missing | 10 | 1 | 3 | 0 | 6 | |
| III and IV vs I and II, OR (95% CI) | – | 1.27 (0.64 to 2.52) | 0.79 (0.39 to 1.58) | 1.17 (0.63 to 2.19) | 1.00 (reference) | |
| Grade | ||||||
| I and II | 342 (71.6) | 54 (62.1) | 76 (66.1) | 90 (71.4) | 122 (81.3) | .006 |
| III | 136 (28.5) | 33 (37.9) | 39 (33.9) | 36 (28.6) | 28 (18.7) | |
| Missing | 14 | 2 | 4 | 1 | 7 | |
| III vs I and II OR (95% CI) | – | 2.66 (1.47 to 4.84) | 2.24 (1.27 to 3.93) | 1.74 (0.99 to 3.06) | 1.00 (reference) | |
*
Two-sided chi-square P values exclude participants with missing data. CI = confidence interval; HER2 = human epidermal growth factor receptor 2; OR = odds ratio.